Most people start noticing weight loss from Wegovy within the first four to eight weeks, though the results at that stage are modest. The medication works on a slow dose-escalation schedule, so meaningful, visible changes typically emerge around months three to four as the dose increases. Maximum weight loss tends to occur around 60 weeks (roughly 14 months) before results plateau.
Why Results Start Slowly
Wegovy uses a gradual dose increase designed to help your body adjust and reduce side effects like nausea. You start at 0.25 mg once weekly, which is well below the target dose. Every four weeks, the dose steps up: 0.25 mg, then 0.5 mg, then 1 mg, then 1.7 mg, and finally the maintenance dose of 2.4 mg. That escalation alone takes about four months before you’re on the full therapeutic dose. A higher-dose option of 7.2 mg is also available for people who need additional effect.
During the early low-dose weeks, the medication is already working. Semaglutide mimics a hormone your gut naturally releases after eating, which signals fullness to your brain and slows how quickly food leaves your stomach. Even at 0.25 mg, many people notice reduced appetite and smaller portion sizes. But because the dose is a fraction of the maintenance level, weight loss in the first month is often just one to two percent of body weight.
What to Expect Month by Month
In the first month at 0.25 mg, the most common change people report is appetite suppression rather than dramatic weight loss. You might lose two to four pounds, though some people lose more and others barely see the scale move. This phase is really about letting your body acclimate to the medication and managing any gastrointestinal side effects.
By months two and three, as the dose climbs to 0.5 mg and then 1 mg, weight loss becomes more noticeable. Clinical trials of semaglutide 2.4 mg showed average weight loss of about five percent of starting body weight by around week 12. For someone who weighs 220 pounds, that’s roughly 11 pounds. This is often the point where friends or coworkers start to notice a change, and where clothing fits differently.
Months four and five mark the transition to the higher doses of 1.7 mg and then 2.4 mg. The appetite-suppressing effects become stronger, and the rate of weight loss picks up. By the six-month mark, participants in the landmark STEP 1 trial had lost an average of about 10 to 12 percent of their body weight. That’s roughly 22 to 26 pounds for someone starting at 220 pounds.
When Weight Loss Peaks
Weight loss from Wegovy doesn’t happen all at once and then stop. It follows a curve: rapid progress in the middle months, gradually slowing as your body adapts. In a 2022 clinical trial, people taking semaglutide hit their weight loss plateau about 60 weeks after starting the medication. That’s just over a year of continued, progressive loss before the numbers level off.
At that plateau point, participants in the STEP 1 trial had lost an average of about 15 percent of their starting body weight, with some losing considerably more. About a third of participants lost 20 percent or more. Individual results vary widely depending on starting weight, diet, physical activity, genetics, and how well the medication is tolerated. Some people reach their plateau earlier, around 9 to 10 months, while others continue losing weight past the 60-week mark.
Factors That Affect Your Timeline
The dose escalation schedule is the single biggest factor in how quickly you see results. If side effects force you to stay at a lower dose longer, or if your prescriber slows the titration, your timeline stretches. Some people can’t tolerate the full 2.4 mg dose and stay at 1.7 mg, which still produces weight loss but at a slower pace and with a lower total amount.
What you eat matters more than many people expect. Wegovy reduces appetite and cravings, but it doesn’t override every food choice. People who combine the medication with a lower-calorie, higher-protein diet consistently lose more weight in trials than those who rely on appetite suppression alone. Physical activity accelerates results too, though its effect on the scale is smaller than its effect on body composition. You may lose the same number of pounds but look noticeably different if you’re exercising regularly.
Starting weight also plays a role. People with more weight to lose tend to see larger absolute losses, especially in the first several months. Metabolic factors like insulin resistance can slow progress early on, though semaglutide also improves insulin sensitivity over time, which can unlock further results as treatment continues.
What Happens After the Plateau
Once weight loss levels off around the 60-week mark, the medication shifts from a weight-loss tool to a weight-maintenance tool. This is a normal and expected phase, not a sign that Wegovy has stopped working. The medication continues to suppress appetite and regulate blood sugar, which helps prevent regain.
Studies that followed participants after stopping semaglutide found that people regained about two-thirds of their lost weight within a year of discontinuation. This is why most prescribers recommend staying on the medication long-term if it’s well tolerated and insurance or cost allows. The plateau isn’t a reason to stop. It’s the medication doing exactly what it’s designed to do at that stage: holding your new weight steady against your body’s natural drive to return to its previous set point.
Non-Scale Changes to Watch For
Weight on the scale is the most obvious metric, but many of the benefits of Wegovy show up in other ways, sometimes before the scale moves significantly. Blood sugar levels often improve within the first few weeks, even at the lowest dose. Blood pressure and cholesterol markers tend to shift favorably by months two to three. Improvements in energy, sleep quality, and joint pain are commonly reported within the first couple of months as well.
Waist circumference often decreases faster than total body weight suggests, because semaglutide appears to preferentially reduce visceral fat (the deep abdominal fat that surrounds organs and drives metabolic disease). If you’re tracking progress, measuring your waist weekly can give you a more encouraging picture than the scale alone, especially during the early low-dose phase.